文拉法辛联合氨磺必利治疗重度抑郁症的疗效及安全性研究

Study on the efficacy and safety of venlafaxinecombined with amisulpride in the treatment ofmajor depression

目的探究文拉法辛联合氨磺必利治疗重度抑郁症患者的临床效果与安全性。方法选取2018年11月至2019年11月本院收治的重度抑郁症患者50例作为研究对象,采用随机列表法分为两组,各25例。对照组采用文拉法辛治疗,研究组在对照组基础上采用氨磺必利治疗,比较两组临床治疗效果与安全性。结果研究组治疗有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组患者抑郁自评量表评分(self-rating depression scale,SDS)均有所降低,且研究组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组患者白细胞介素-18(IL-18)水平均降低,且研究组低于对照组,差异有统计学意义(P<0.05)。研究组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论采用文拉法辛联合氨磺必利治疗重度抑郁症患者,可有效提升患者治疗效果与安全性,对于患者具有积极意义,值得推广应用。

Objective To analyze the clinical effect and safety of combined treatment of venlafaxine and amisulpride in the treatment of patients with major depression.Methods From November 2018 to November 2019,50 patients with severe depression who were admitted to our hospital were selected as the research subjects,and they were divided into two groups according to random list method,with 25 cases in each group.The control group was treated with venlafaxine,the study group was treated with amisulpride on the basis of the control group.The clinical efficacy and safety between the two groups were recorded and compared.Results The effective rate of the study group was higher than that of the control group,the difference was statistically significant(P<0.05).After treatment,the self rating depression scale(SDS)of the two groups decreased,and the study group was lower than the control group,the difference was statistically significant(P<0.05).After treatment,the levels of interleukin-18(IL-18)in the two groups were decreased,and the study group was lower than the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group was lower than that in the control group(P<0.05).Conclusion In the treatment of patients with major depression,combined treatment with venlafaxine and amisulpride can effectively improve the treatment effect and safety of patients.It has positive value for patients and is worthy of popularization and application.